The Immunology Biosimilars Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Immunology Biosimilars Market?
The market size for immunology biosimilars has seen substantial growth lately. It is projected to increase from $7.38 billion in 2024 to $8.35 billion in 2025. The compound annual growth rate (CAGR) is expected to be 13.1%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Immunology Biosimilars Industry?
The Immunology Biosimilars Global Market Report 2025 predicts that by 2029, the immunology biosimilars market will grow to a size of $13.57 billion. This growth represents a compound annual growth rate (CAGR) of 12.9%.
Download Your Free Sample of the 2025 Immunology Biosimilars Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Immunology Biosimilars Market?
The key drivers in the immunology biosimilars market are:
• Rising prevalence of chronic immunological conditions
• Growing need for continuous treatment and proactive disease management
• Presence of affordable and effective treatment alternatives with biosimilars
• Improved patient access to essential therapies controlling immune system dysfunction
Global Market Segmentation: Identifying Major Immunology Biosimilars Industry Segments
The immunology biosimilars market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Fusion Proteins, Recombinant Proteins, Interferons, Other Biosimilar Immunomodulators
2) By Disease: Inflammatory Bowel Disease, Arthritis, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End User: Hospitals, Clinics, Homecare Settings, Ambulatory Surgical Centers (ASCs)
Pre-order the 2025 Immunology Biosimilars Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Immunology Biosimilars Market?
The key trends in the immunology biosimilars market are:
• There is an emerging trend towards the development of next-generation biosimilar innovations, which include anticipated interchangeability designation, advanced formulations with enhanced stability, and novel delivery systems.
• An increased focus is seen on creating more accessible and effective treatment options for patients.
• Pharmaceuticals are aiming for anticipated interchangeability designation, which would allow the biosimilar to meet regulatory standards and be substituted for the reference biologic at the pharmacy level without the prescriber’s intervention.
• The expansion of access to immunology biosimilars is seen as a major focus, combining cost-effectiveness and patient-centric therapy with multiple dosing options, extended stability and the unique ability to be re-refrigerated after initial refrigeration.
Who Are the Top Competitors & Leading Players in the Immunology Biosimilars Market?
Major players in the immunology biosimilars market are:
• Pfizer Inc.
• Novartis AG
• LG Chem Ltd.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Sandoz Group AG
• Fresenius Kabi AG
• Intas Pharmaceuticals Ltd.
• Stada Arzneimittel AG
• Cipla Ltd.
• Kyowa Kirin Co. Ltd.
• Dr. Reddy's Laboratories Ltd.
• Samsung Bioepis Co. Ltd.
• Gedeon Richter Plc
• Celltrion Inc.
• Biocon Ltd.
• Innovent Biologics Inc.
• Biocad
• Mabion S.A.
Regional Dominance: Which Area Leads the Global Immunology Biosimilars Market?
North America was the largest region in the immunology biosimilars market in 2024
